Evergreen Capital Management LLC lessened its stake in Amgen Inc. (NASDAQ: AMGN – Get Rating) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,458 shares of the medical research company stock after selling 126 shares during the period. Evergreen Capital Management LLC’s holdings in Amgen were worth $ 2,353,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of AMGN. Norges Bank bought a new stake in Amgen during the fourth quarter valued at $ 1,138,930,000. BlackRock Inc. increased its stake in Amgen by 2.1% during the fourth quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company stock valued at $ 11,258,926,000 after purchasing an additional 1,032,929 shares during the last quarter. Barclays PLC increased its stake in Amgen by 48.0% during the fourth quarter. Barclays PLC now owns 3,033,778 shares of the medical research company stock valued at $ 682,507,000 after purchasing an additional 984,406 shares during the last quarter. Renaissance Technologies LLC increased its stake in Amgen by 625.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,101,853 shares of the medical research company stock valued at $ 247,884,000 after purchasing an additional 950,008 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in Amgen by 125.5% during the fourth quarter. First Trust Advisors LP now owns 1,613,704 shares of the medical research company stock valued at $ 363,035,000 after purchasing an additional 898,059 shares during the last quarter. Institutional investors and hedge funds own 79.01% of the company stock.
Shares of NASDAQ AMGN opened at $ 234.72 on Friday. Amgen Inc. has a twelve month low of $ 198.64 and a twelve month high of $ 258.45. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. The company has a market capitalization of $ 125.39 billion, a price-to-earnings ratio of 23.10, a PEG ratio of 2.01 and a beta of 0.57. The firm has a 50-day moving average of $ 245.45 and a two-hundred day moving average of $ 234.17.
Amgen (NASDAQ: AMGN – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The medical research company reported $ 4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $ 4.22 by $ 0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The company had revenue of $ 6.24 billion during the quarter, compared to the estimate consensus of $ 6.09 billion. During the same period in the prior year, the company earned $ 3.70 EPS. As a group, research analysts predict that Amgen Inc. will post 17.44 earnings per share for the current year.
AMGN has been the subject of several recent research reports. Barclays boosted their target price on shares of Amgen from $ 233.00 to $ 236.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. Morgan Stanley reduced their price target on shares of Amgen from $ 238.00 to $ 237.00 and set an “equal weight” rating for the company in a report on Tuesday, April 12th. TheStreet downgraded shares of Amgen from a “b +” rating to a “c +” rating in a report on Wednesday, April 27th. Mizuho boosted their price target on shares of Amgen from $ 202.00 to $ 208.00 in a report on Tuesday, May 10th. Finally, Oppenheimer boosted their price target on shares of Amgen from $ 285.00 to $ 290.00 and gave the company an “outperform” rating in a report on Wednesday, June 1st. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and an average target price of $ 242.57.
In other Amgen news, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $ 250.00, for a total transaction of $ 150,000.00. Following the sale, the director now owns 5,501 shares in the company, valued at approximately $ 1,375,250. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $ 241.81, for a total value of $ 3,264,435.00. Following the sale, the executive vice president now owns 37,333 shares in the company, valued at approximately $ 9,027,492.73. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by corporate insiders.
About Amgen: (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology / hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due to a low white blood cell count in cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ: AMGN – Get Rating).
Receive News & Ratings for Amgen Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.